Recombinant PTH reduces fractures

Nycomed has launched Preotact, a recombinant human parathyroid hormone licensed for the treatment of osteoporosis in postmenopausal women at high risk of fractures.

The recommended dose of Preotact is 100 micrograms once daily self administered by the patient as a subcutaneous injection into the abdomen.

Trials in women with postmenopausal osteoporosis at this dose level and receiving daily calcium and vitamin D supplements for a period of 18 months produced a significant reduction in the incidence of vertebral fractures, but not in the incidence of non-vertebral fractures. Risk reduction of vertebral fractures was highest in those women with previous fractures and in those with a lumbar spine T-score of less than -3.

Further information: Nycomed UK Ltd, The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA. Tel: 01865 784500.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases